Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Gynecology

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777649

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777649

Uterine Fibroid Treatment Drugs

PUBLISHED:
PAGES: 376 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Uterine Fibroid Treatment Drugs Market to Reach US$3.6 Billion by 2030

The global market for Uterine Fibroid Treatment Drugs estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Gonadotropin-releasing Hormone Agonists, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Gonadotropin-releasing Hormone Antagonists segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$577.7 Million While China is Forecast to Grow at 14.2% CAGR

The Uterine Fibroid Treatment Drugs market in the U.S. is estimated at US$577.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$789.3 Million by the year 2030 trailing a CAGR of 14.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.

Global Uterine Fibroid Treatment Drugs Market - Key Trends & Drivers Summarized

Is the Rising Prevalence of Uterine Fibroids Reshaping the Demand for Drug-Based Therapies?

Uterine fibroids, or leiomyomas, are one of the most common benign tumors in women of reproductive age, with an estimated global prevalence affecting nearly 20% to 40% of women. The rising awareness, improved diagnosis, and increased healthcare access have significantly boosted the number of women seeking treatment for fibroid-related symptoms such as heavy menstrual bleeding, pelvic pain, infertility, and anemia. As many patients look for alternatives to invasive surgical procedures such as hysterectomy and myomectomy, pharmaceutical interventions are gaining renewed traction. This shift in patient preference has significantly expanded the demand for uterine fibroid treatment drugs as first-line or pre-surgical management options. With fibroids more commonly affecting women in their 30s and 40s-many of whom are still in their childbearing years-preserving fertility and avoiding long recovery times has become a central concern, further propelling the need for effective, non-surgical therapies. Ethnic disparities particularly higher incidence and severity among women of African descent are also contributing to a growing patient pool in underserved and high-risk communities. These demographic and clinical dynamics are creating a robust foundation for sustained growth in the drug-based treatment segment for uterine fibroids.

How Are Novel Drug Classes and Hormonal Agents Advancing Therapeutic Options?

Pharmaceutical innovation is rapidly transforming the landscape of uterine fibroid treatment, with new and improved drugs offering enhanced symptom control, fewer side effects, and greater convenience. Gonadotropin-releasing hormone (GnRH) analogs have long been used to reduce fibroid size and manage heavy bleeding, but their association with hypoestrogenic side effects like bone loss and hot flashes has limited long-term use. This has paved the way for newer therapies such as selective progesterone receptor modulators (SPRMs) and oral GnRH antagonists, which offer more targeted hormonal modulation with improved safety profiles. Drugs like relugolix, often used in combination with estradiol and norethindrone, are now emerging as effective oral therapies that balance efficacy with patient tolerability. These novel agents are enabling long-term symptom management and are increasingly being prescribed as alternatives or adjuncts to surgical intervention. In parallel, advancements in drug delivery mechanisms-such as extended-release formulations and combination therapies-are enhancing patient adherence and expanding options for individualized care. With ongoing clinical trials exploring new hormone regulators, anti-fibrotic agents, and even immune-modulating therapies, the pharmaceutical pipeline for uterine fibroid treatment is more dynamic than ever. These innovations are not only improving therapeutic outcomes but are also reinforcing the market’s shift toward personalized, non-invasive fibroid management.

Are Shifting Patient Preferences and Healthcare Models Driving Non-Surgical Treatment Adoption?

The growing global emphasis on patient-centered, minimally invasive care is fundamentally changing how uterine fibroids are managed-putting greater focus on drug-based interventions. Increasingly, women are demanding treatment options that allow them to preserve their uterus, maintain fertility, and avoid extended downtime associated with surgery. This has made pharmacological therapies an attractive choice, particularly for those with mild to moderate symptoms or those awaiting surgery. Moreover, the evolution of outpatient care models and the expansion of telemedicine platforms are facilitating remote diagnosis, follow-up, and prescription of fibroid treatment drugs, making therapies more accessible even in lower-resource settings. Direct-to-consumer health platforms and digital wellness brands are also playing a role in demystifying menstrual health and fibroid awareness, encouraging more women to pursue medical treatment earlier. Furthermore, the ability to combine drug therapy with other non-invasive procedures, such as uterine artery embolization (UAE) or focused ultrasound surgery (FUS), is giving patients and providers more flexibility in treatment planning. In response, pharmaceutical companies are increasingly focusing on education, patient support programs, and community outreach to encourage adherence and improve outcomes. This patient-driven momentum is contributing to a more diversified and inclusive market landscape, where drug therapies serve as both standalone solutions and components of broader multimodal treatment strategies.

What Factors Are Driving Long-Term Growth in the Uterine Fibroid Treatment Drugs Market?

The growth in the uterine fibroid treatment drugs market is driven by a combination of clinical need, technological progress, changing patient demographics, and evolving healthcare delivery systems. A key driver is the increasing global prevalence of fibroids, particularly among women aged 30 to 50, a demographic that is highly active in seeking care and maintaining reproductive health. The expanding pipeline of targeted hormonal therapies, including SPRMs and oral GnRH antagonists, is providing safer, more convenient options for long-term management, thus drawing greater interest from both patients and providers. Healthcare systems around the world are also shifting toward non-surgical management of chronic conditions, creating a favorable environment for the adoption of drug-based fibroid therapies. Additionally, growing awareness campaigns and women's health advocacy efforts are improving education and reducing stigma around menstrual health, leading to earlier diagnosis and greater demand for pharmacologic solutions. Reimbursement approvals and regulatory endorsements in key markets like the U.S., Europe, and Japan are also bolstering product accessibility and commercial viability. Investment from major pharmaceutical companies and biotech startups alike is fueling research and development, while digital health platforms are enabling broader distribution and patient engagement. Together, these factors are ensuring that the uterine fibroid treatment drugs market continues to grow, driven by innovation, accessibility, and an increasingly empowered global patient population.

SCOPE OF STUDY:

The report analyzes the Uterine Fibroid Treatment Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications, Others); Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids); End-User (Hospital Pharmacies, Retail Pharmacies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Abbott Healthcare Pvt. Ltd.
  • Amring Pharmaceuticals Inc.
  • AstraZeneca
  • Bayer AG
  • Biocon Biologics
  • Bristol-Myers Squibb Company
  • Ferring Pharmaceuticals
  • Gedeon Richter plc
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Kissei Pharmaceutical Co., Ltd.
  • Medtronic
  • Merot Medical Systems
  • Minerva Surgical, Inc.
  • Myovant Sciences GmbH
  • Novartis AG
  • ObsEva

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP33214

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Uterine Fibroid Treatment Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Uterine Fibroids Spurs Sustained Demand for Drug-Based Treatment Alternatives
    • Increased Preference for Fertility-Preserving and Non-Surgical Therapies Strengthens Business Case for Pharmacologic Options
    • Advancements in Hormonal Drug Classes and Targeted Therapies Propel Innovation in Symptom Management
    • Growing Patient Awareness and Early Diagnosis Trends Expand the Addressable Market for Medical Treatment
    • Shift Toward Personalized Medicine and Symptom-Specific Formulations Drives Adoption Among Reproductive-Age Women
    • Postponement of Childbearing and Changing Reproductive Health Trends Fuel Demand for Uterus-Conserving Therapies
    • Regulatory Approvals and Market Entry of Oral GnRH Antagonists Create New Competitive Opportunities
    • Expansion of Telehealth and Direct-to-Consumer Gynecology Services Accelerates Access to Treatment Options
    • Rising Investments in Women's Health Research and Drug Development Strengthen the Therapeutic Pipeline
    • Increased Emphasis on Quality of Life and Menstrual Health Throws Spotlight on Long-Term Medical Management Solutions
    • Combination Therapy Approaches Generate Opportunities for Multifaceted and Extended Treatment Plans
    • Digital Education Campaigns and Advocacy Efforts Drive Patient Engagement and Reduce Stigma Around Fibroid Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Uterine Fibroid Treatment Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Gonadotropin-releasing Hormone Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Gonadotropin-releasing Hormone Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gonadotropin-releasing Hormone Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Gonadotropin-releasing Hormone Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Progestin-releasing Intrauterine Device & Contraceptives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Non-hormonal Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Non-hormonal Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Subserosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Subserosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Intramural Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Intramural Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Submucosal Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Submucosal Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Pedunculated Fibroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Pedunculated Fibroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • JAPAN
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • CHINA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • EUROPE
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • FRANCE
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • GERMANY
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • INDIA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030
  • AFRICA
    • Uterine Fibroid Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Uterine Fibroid Treatment Drugs by Drug Class - Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Gonadotropin-releasing Hormone Agonists, Gonadotropin-releasing Hormone Antagonists, Progestin-releasing Intrauterine Device & Contraceptives, Non-hormonal Medications and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Uterine Fibroid Treatment Drugs by End-user - Hospital Pharmacies, Retail Pharmacies and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by End-user - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Uterine Fibroid Treatment Drugs by Type - Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Uterine Fibroid Treatment Drugs by Type - Percentage Breakdown of Value Sales for Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and Pedunculated Fibroids for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!